Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 6 Gy Clear all
Withdrawn Phase 2 Interventional

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

NCT03149159
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, Steriotactic radiation therapy
Drug · Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

NCT03661723
View directory record Official record
Conditions
Glioblastoma
Interventions
Pembrolizumab, Bevacizumab, Re-irradiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Not applicable Interventional Results available

Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer

NCT01576939
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 31, 2026, 7:56 PM EDT
Recruiting Phase 1 Interventional

d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC

NCT04392622
View directory record Official record
Conditions
Xerostomia
Interventions
D-Limonene Gelcaps, Intensity modulated radiotherapy (IMRT), Cisplatin, Xerostomia questionnaire
Drug · Radiation · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

NCT03621696
View directory record Official record
Conditions
HPV Related Oropharyngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Intensity modulated radiation therapy, Intensity modulated proton therapy, Surgery, FACT-H&N, MD Anderson Dysphagia Inventory, University of Michigan Xerostomia Index, Scale of Subjective Total Taste Acuity, Neck Dissection Impairment Index
Drug · Radiation · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

NCT03137888
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Dose-Escalated Radiation Therapy, Spectroscopic Magnetic Resonance Imaging, Temozolomide
Radiation · Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

NCT00185965
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Mycosis Fungoides
Interventions
CPG 7909
Drug
Lead sponsor
Ronald Levy
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

NCT03532295
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Epacadostat, Bevacizumab, Radiation therapy, Retifanlimab
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 31, 2026, 7:56 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT01822496
View directory record Official record
Conditions
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions
Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
174
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 2 Interventional

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

NCT00318903
View directory record Official record
Conditions
Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer, Esophageal Neoplasm, Cancer of Esophagus
Interventions
Irinotecan (drug), Taxotere (drug), Radiotherapy (procedure), Esophagectomy (procedure)
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 31, 2026, 7:56 PM EDT
Terminated Phase 3 Interventional Results available

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

NCT03056638
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, stereotactic body radiosurgery (SBRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Not applicable Interventional

Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

NCT01117935
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
intensity modulated external beam radiation therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 31, 2026, 7:56 PM EDT
Active, not recruiting Phase 2 Interventional

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

NCT00715611
View directory record Official record
Conditions
Mesothelioma
Interventions
Pleurectomy/Decortication, pemetrexed and cisplatin or carboplatin, Intensity Modulated Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
12
States / cities
Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT03132532
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

NCT03481114
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PET-based, dose-painted, accelerated chemoradiotherapy, Standard chemoradiotherapy
Combination Product
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 31, 2026, 7:56 PM EDT
Recruiting Phase 1 Interventional

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

NCT05296304
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma
Interventions
Bexarotene, Total Skin Electron Beam (TSEB)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Commack, New York • New York, New York • Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 31, 2026, 7:56 PM EDT
Terminated Phase 1 Interventional Results available

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

NCT06056310
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Not applicable Interventional

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

NCT01526603
View directory record Official record
Conditions
Neuroblastoma
Interventions
Carboplatin, Autologous stem cell infusion, Granulocyte colony stimulating factor, Radiation therapy, Isotretinoin (13-cis-retinoic acid), Melphalan, Etoposide
Drug · Biological · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 31, 2026, 7:56 PM EDT
Recruiting Phase 1 Interventional

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

NCT06624371
View directory record Official record
Conditions
High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
Atovaquone, Radiation Therapy
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
2 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 31, 2026, 7:56 PM EDT
Recruiting Phase 2Phase 3 Interventional

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

NCT05288777
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
T-DM1, Capecitabine, External Beam Radiation Therapy 0, External Beam Radiation Therapy 1
Drug · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

NCT00590031
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Cisplatin, Irinotecan, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 31, 2026, 7:56 PM EDT
Active, not recruiting Phase 1 Interventional

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

NCT05109728
View directory record Official record
Conditions
Glioblastoma
Interventions
[177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide, Radiotherapy
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 31, 2026, 7:56 PM EDT
Completed Phase 1 Interventional

Stereotactic Radiosurgery in Treating Patients With Spinal Metastases

NCT00853528
View directory record Official record
Conditions
Metastatic Cancer
Interventions
questionnaire administration, diffusion tensor imaging, functional magnetic resonance imaging, hypo-fractionated SRS, single-fraction SRS
Other · Procedure · Radiation
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 31, 2026, 7:56 PM EDT
Recruiting Phase 1 Interventional

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

NCT04389281
View directory record Official record
Conditions
Advanced Solid Tumor Cancer
Interventions
X-PACT
Combination Product
Lead sponsor
Immunolight, LLC
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 31, 2026, 7:56 PM EDT